Conference Coverage

Fractional flow reserve-guided PCI improves outcomes in stable heart disease

View on the News

Stenting significant lesions might prevent events

The most impressive finding in the FAME 2 trial was a sustained reduced rate of urgent revascularization among patients undergoing early PCI.

Though the trigger in 60% of patients was based solely on clinical features and was potentially influenced by knowledge of the coronary anatomy, there was nonetheless a lower incidence of revascularization triggered by myocardial infarction or electrocardiographic changes in the PCI group than in the medical therapy group (3.4% versus 7.0%). This finding is consistent with recent evidence challenging the long-held view that acute coronary syndromes occur mainly at sites of noncritical stenoses.

It is plausible that stenting of vulnerable, hemodynamically significant lesions could prevent future coronary events.

The FAME 2 results show that early FFR-guided PCI in patients with stable coronary disease sustainably reduced the need for urgent revascularization. Given the continued improvement in the safety of stents and the procedures to implant them, PCI may eventually be shown to also have a favorable effect on other hard end points.

Dr. Jeffrey J. Rade is with the University of Massachusetts, Worcester. He made these comments in an accompanying editorial (N. Engl. J. Med. 2014 Sept. 1[doi:10.1056/NEJMe1410336]). He reported having no disclosures.


 

FROM THE ESC CONGRESS 2014

References

Fractional flow reserve-guided percutaneous coronary intervention plus best medical therapy improved outcomes when compared with medical therapy alone in patients with stable coronary artery disease in the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 (FAME 2) trial.

A composite outcome of death from any cause, nonfatal myocardial infarction, or urgent revascularization within 2 years occurred in 8.1% of 447 patients who had at least one stenosis with a fractional flow reserve (FFR) of 0.80 and were randomized to undergo percutaneous coronary intervention (PCI) performed on the basis of the FFR, compared with 19.5% of 441 such patients who received medical therapy alone.

The difference was driven mainly by a 77% reduction in the need for urgent revascularization in interventional group as compared with the medical therapy group (4.0% vs. 16.3%, hazard ratio, 0.23). The overall rates of death and myocardial infarction did not differ significantly between the groups, Dr. Bernard D. Bruyne of the Cardiovascular Center Aalst, Belgium, and his colleagues reported at the annual congress of the European Society of Cardiology.

The findings of the open-label, randomized, multicenter trial were simultaneously published online Sept. 1 (N. Engl. J. Med. 2014 Sept. 1[doi:10.1056/NEJMoa1408758]).

The improved outcomes in the PCI group were the result of outcomes that occurred between 8 days and 2 years after randomization; in the first 7 days, more primary end-point events occurred in the PCI group than in the medical therapy group (2.2% vs. 0.9%, hazard ratio 2.49).

The rate of the primary endpoint was 9.0% among 332 additional patients who had an FFR of more than 0.80 in all stenoses, were enrolled into a registry, and received medical therapy alone, the researchers said.

The original FAME trial studied the procedure in patients who had already been selected for PCI. Compared with patients whose PCI was guided by angiography alone, those whose PCI was guided by FFR had significantly reduced rates of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year (N. Engl. J. Med. 2009;360:213-24).

FAME 2 evaluated use of FFR for improving the benefits of initial stenting as an alternative to noninvasive medical therapy. The trial was halted after a median of 7 months’ follow-up, when data safety and monitoring board found a highly statistically significant reduction in hospital readmission and urgent revascularization in the patients who received FFR-based stenting compared with those who received optimal medical therapy alone.

FAME 2 was supported by St. Jude Medical. Dr. De Bruyne reported that his institution receives grant support and consulting fees on his behalf from St. Jude Medical. Detailed disclosure information for several other authors is available with the full text of the article at www.NEJM.org.

Recommended Reading

Elderly CAD patients benefit from a systolic value below 140 mm Hg
MDedge Family Medicine
Lipid screening uncommon before 2011 recommendations
MDedge Family Medicine
USPSTF: Offer behavioral counseling to prevent cardiovascular disease
MDedge Family Medicine
AHA wants e-cigarettes regulated but notes they help some smokers quit
MDedge Family Medicine
New cholesterol guideline outperforms ATP III
MDedge Family Medicine
Typical risk factors don’t always red-flag coronary disease in IBD patients
MDedge Family Medicine
Aortic dissection associated with obstructive sleep apnea syndrome
MDedge Family Medicine
WHO to push for public ban of e-cigarettes
MDedge Family Medicine
SIGNIFY: Ivabradine no help in stable CAD
MDedge Family Medicine
ACC/AHA risk calculator compares well with European SCORE
MDedge Family Medicine